Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $14.00

SAB Biotherapeutics (NASDAQ:SABS) had its target price boosted by analysts at Chardan Capital from $12.00 to $14.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s target price would suggest a potential upside of 206.01% from the stock’s previous close.

Other analysts also recently issued reports about the company. Wall Street Zen raised SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. HC Wainwright decreased their price objective on SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. UBS Group began coverage on shares of SAB Biotherapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Guggenheim assumed coverage on shares of SAB Biotherapeutics in a research note on Friday, December 19th. They issued a “buy” rating and a $15.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

SAB Biotherapeutics Stock Up 11.6%

SABS traded up $0.48 during mid-day trading on Wednesday, reaching $4.58. 2,522,939 shares of the stock were exchanged, compared to its average volume of 455,720. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $6.60. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 10.49. The stock has a market capitalization of $217.82 million, a PE ratio of -1.96 and a beta of 0.59. The company has a 50 day moving average price of $3.98 and a two-hundred day moving average price of $3.33.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). As a group, research analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vivo Capital LLC purchased a new position in shares of SAB Biotherapeutics during the 3rd quarter valued at $22,954,000. RA Capital Management L.P. purchased a new stake in shares of SAB Biotherapeutics in the third quarter worth $8,847,000. Commodore Capital LP bought a new stake in SAB Biotherapeutics during the third quarter valued at $8,847,000. Woodline Partners LP purchased a new position in SAB Biotherapeutics during the third quarter worth about $5,730,000. Finally, Spruce Street Capital LP bought a new position in SAB Biotherapeutics in the 4th quarter worth about $8,222,000. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.